Rigel Pharmaceuticals, Inc. (RIGL) is a Biotechnology company in the Healthcare sector, currently trading at $31.39. It has a SharesGrow Score of 78/100, indicating a strong investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of RIGL = $55.53 (+76.9% from the current price, the stock appears undervalued). Analyst consensus target is RIGL = $40 (+27.4% upside).
Valuation: RIGL trades at a trailing Price-to-Earnings (P/E) of 1.5 (S&P 500 average ~25).
Financials: revenue is $294M, +38.2%/yr average growth. Net income is $367M, growing at +742%/yr. Net profit margin is 124.7% (strong). Gross margin is 93.3% (-5.2 pp trend).
Balance sheet: total debt is $53M against $391M equity (Debt-to-Equity (D/E) ratio 0.14, conservative). Current ratio is 2.42 (strong liquidity). Debt-to-assets is 10.4%. Total assets: $514M.
Analyst outlook: 8 / 15 analysts rate RIGL as buy (53%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 100/100 (Pass), Past 50/100 (Partial), Health 100/100 (Pass), Moat 49/100 (Partial), Future 58/100 (Partial), Income 100/100 (Pass).
